Lucid Diagnostics Inc
NASDAQ:LUCD
Operating Margin
Lucid Diagnostics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
L
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
99.5m USD |
-1 060%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
221.6B USD |
17%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
174.6B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
138.9B USD |
18%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
134.8B USD |
22%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
108.1B USD |
19%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.7B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
50.2B EUR |
13%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
41.1B USD |
27%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
259.1B CNY |
36%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
33B USD |
29%
|
Lucid Diagnostics Inc
Glance View
Lucid Diagnostics, Inc. develops medical testing devices. The company is headquartered in New York City, New York. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Its products include EsoCheck and EsoGuard. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in an office procedure. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next generation sequencing (NGS) deoxyribonucleic acid (DNA) assay performed on surface esophageal cells collected with EsoCheck. The firm is a subsidiary of PAVmed Inc.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Lucid Diagnostics Inc's most recent financial statements, the company has Operating Margin of -1 059.6%.
You don't have any saved screeners yet